APREA THERAPEUTICS, INC. (APRE): Price and Financial Metrics
APRE Price/Volume Stats
| Current price | $5.35 | 52-week high | $8.85 |
| Prev. close | $5.17 | 52-week low | $2.78 |
| Day low | $5.02 | Volume | 9,000 |
| Day high | $5.47 | Avg. volume | 29,319 |
| 50-day MA | $6.40 | Dividend yield | N/A |
| 200-day MA | $4.79 | Market Cap | 29.05M |
APRE Stock Price Chart Interactive Chart >
APREA THERAPEUTICS, INC. (APRE) Company Bio
Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Aprea Therapeutics serves customers in the United States and Sweden.
Latest APRE News From Around the Web
Below are the latest news stories about APREA THERAPEUTICS INC that investors may wish to consider to help them evaluate APRE as an investment opportunity.
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business UpdateDOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the three and nine months ended September 30, 2023, and provided a business update. “We are very pleased by the progress of our diversified programs this past quarter. Importantly, we presented initial clinical data from our Phase 1/2a study |
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) PathwaysEvent featuring Fiona Simpkins, M.D. and Timothy A. Yap, MBBS, PhD, FRCP to take place on October 31, 2023 at 11:00 am ETDOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced it will host a KOL event on Tuesday, October 31, 2023 at 11:00 am ET. The program will feature Dr. Fiona Simpkins, Perelman School of Medicin |
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality PortfolioDOYLESTOWN, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced highlights of two posters presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 14, 2023 in Boston, MA. The data in the posters include first-in-human clinical data from the ongoing Phase 1 dose escalation |
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsDOYLESTOWN, Pa., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced two poster presentations at the upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held on October 11-15, 2023, in Boston, MA. Aprea is in development with two assets. Its lead program is ATRN-119, a clinica |
Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 InhibitorsDemonstrating potential safety and efficacy of WEE1 inhibitor, ATRN-1051, in the treatment of ovarian cancer Company anticipates submitting an IND by the end of 2023 Data to be presented at an upcoming 2023 scientific conference, with KOL event planned for the fall DOYLESTOWN, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today annou |
APRE Price Returns
| 1-mo | -9.63% |
| 3-mo | 2.88% |
| 6-mo | 51.22% |
| 1-year | 40.05% |
| 3-year | -94.45% |
| 5-year | N/A |
| YTD | 13.83% |
| 2023 | -29.00% |
| 2022 | -88.47% |
| 2021 | -41.67% |
| 2020 | -89.28% |
| 2019 | N/A |
Loading social stream, please wait...